Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) traded up 13.6% during trading on Wednesday. The stock traded as high as $8.68 and last traded at $8.7350. 729,159 shares were traded during trading, a decline of 49% from the average daily volume of 1,426,370 shares. The stock had previously closed at $7.69.
REGENXBIO News Summary
These are some of the RGNX news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.15 from a loss of $3.65, while maintaining its Buy rating. REGENXBIO analyst coverage
- Neutral Sentiment: A short-interest update reports zero shares sold short and zero days to cover, despite describing a “significant increase.” The conflicting wording makes the data difficult to interpret and does not provide a clear directional signal.
- Negative Sentiment: HC Wainwright lowered EPS estimates for Q4 2026 and each quarter of 2027, and cut its FY2027 estimate to a loss of $4.41 from $4.02. The deeper projected losses may weigh on sentiment, although the firm retained its Buy rating. REGENXBIO analyst coverage
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on RGNX. Mizuho set a $18.00 price objective on shares of REGENXBIO in a research note on Friday, November 6th. Zacks Research upgraded shares of REGENXBIO from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Weiss Ratings upgraded shares of REGENXBIO from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Wall Street Zen downgraded shares of REGENXBIO from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Morgan Stanley reissued an "overweight" rating and set a $18.00 target price on shares of REGENXBIO in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of "Moderate Buy" and an average price target of $23.18.
View Our Latest Research Report on RGNX
REGENXBIO Price Performance
The firm's 50 day moving average price is $7.74 and its 200-day moving average price is $8.98. The firm has a market cap of $571.47 million, a price-to-earnings ratio of -2.70 and a beta of 1.24.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.67. REGENXBIO had a negative net margin of 113.85% and a negative return on equity of 203.98%. The firm had revenue of $9.16 million during the quarter, compared to analysts' expectations of $10.89 million. Analysts expect that REGENXBIO Inc. will post -3.10 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in RGNX. BlackRock Inc. bought a new stake in shares of REGENXBIO in the second quarter valued at about $76,641,000. Dimensional Fund Advisors LP increased its stake in REGENXBIO by 11.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,010,381 shares of the biotechnology company's stock valued at $8,464,000 after acquiring an additional 106,530 shares during the period. Bank of America Corp DE acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $6,212,000. Corient Private Wealth LP acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $2,608,000. Finally, Deutsche Bank AG acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $2,490,000. Institutional investors and hedge funds own 88.08% of the company's stock.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients' cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.